[1] Graff-Radford J, Yong KXX, Apostolova LG,et al. New insights into Atypical Alzheimer's disease in the era of biomarkers[J]. Lancet Neurol, 2021 ,20(3):222-234.DOI: 10.1016/S1474-4422(20)30440-3.
[2] Swanson CJ, Zhang Y, Dhadda S,et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody[J]. Alzheimers Res Ther, 2021,13(1):80. DOI: 10.1186/s13195-021-00813-8.
[3] Zaciragic A, Valjevac A, Dervisevic A,et al. Traditional and non-traditional lipid profiles in bosnian patients with probable Alzheimer's disease and vascular dementia[J]. Med Arch, 2022 ,76(4):267-272.DOI: 10.5455/medarh.2022.76.267-272.
[4] Zaciragic A, Dervisevic A, Valjevac A,et al. Difference in the standard and novel lipid profile parameters between patients with Alzheimer's disease and vascular dementia stratified by the degree of cognitive impairment[J]. Mater Sociomed, 2022 ,34(2):100-106.DOI: 10.5455/msm.2022.34.100-106.
[5] Xin Y, Zhang L, Hu J,et al. Correlation of early cognitive dysfunction with inflammatory factors and metabolic indicators in patients with Alzheimer's disease[J]. Am J Transl Res, 2021,13(8):9208-9215.
[6] Serrano-Pozo A, Das S, Hyman BT. APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches[J]. Lancet Neurol, 2021,20(1):68-80.DOI: 10.1016/S1474-4422(20)30412-9.
[7] Raulin AC, Doss SV, Trottier ZA,et al. ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies[J]. Mol Neurodegener, 2022,17(1):72.DOI: 10.1186/s13024- 022-00574-4.
[8] Fernández-Calle R, Konings SC, Frontiñán-Rubio J,et al. APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases[J]. Mol Neurodegener, 2022,17(1):62.DOI: 10.1186/s13024-022-00566-4.
[9] Liu CC, Zhao J, Fu Y,et al. Peripheral apoE4 enhances Alzheimer's pathology and impairs cognition by compromising cerebrovascular function[J]. Nat Neurosci, 2022,25(8):1020-1033.DOI: 10.1038/s41593-022- 01127-0.
[10] Jack CR, Bennett DA, Blennow K,et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease[J]. Alzheimers Dement, 2018 ,14(4):535-562.DOI: 10.1016/j.jalz.2018.02.018.
[11] Jia X, Wang Z, Huang F,et al. A comparison of the mini-mental state examination (MMSE) with the Montreal cognitive assessment (MoCA) for mild cognitive impairment screening in Chinese middle-aged and older population: a cross-sectional study[J]. BMC Psychiatry, 2021,21(1):485.DOI: 10.1186/s12888-021-03495-6.
[12] Palmqvist S, Tideman P, Cullen N,et al. Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures[J]. Nat Med, 2021 ,27(6):1034-1042.DOI: 10.1038/s41591-021- 01348-z.
[13] Zalocusky KA, Najm R, Taubes AL,et al. Neuronal ApoE upregulates MHC-I expression to drive selective neurodegeneration in Alzheimer's disease[J]. Nat Neurosci, 2021,24(6):786-798.DOI: 10.1038/s41593- 021-00851-3.
[14] de Frutos Lucas J, Sewell KR, García-Colomo A,et al. How does apolipoprotein E genotype influence the relationship between physical activity and Alzheimer's disease risk? A novel integrative model[J]. Alzheimers Res Ther, 2023,15(1):22.DOI: 10.1186/s13195-023-01170-4.
[15] Zhang Q, Xie C. Apolipoprotein E drives early blood-brain barrier damage in Alzheimer's disease[J]. Neurosci Bull, 2021 ,37(2):281-283. DOI: 10.1007/s12264-020- 00596-2.
[16] Fagan AM, Henson RL, Li Y,et al. Comparison of CSF biomarkers in down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study[J]. Lancet Neurol, 2021,20(8):615-626.DOI: 10.1016/S1474-4422(21)00139-3.
[17] 马瑞敏,李国歌,丁耀威,等. 阿尔茨海默病患者血脂水平与性别和年龄及载脂蛋白E基因多态性的相关研究[J]. 中华预防医学杂志,2022,56(3):280-286. DOI:10.3760/cma.j.cn112150-20211026-00996.
[18] 谷愉愉,王丹,龚晨,等. ApoE基因多态性与轻度认知障碍的相关性研究[J]. 标记免疫分析与临床,2021,28(1):5-10. DOI:10.11748/bjmy.issn.1006-1703.2021.01.002.
[19] Abdi S, Alghamdi AA, AlGhunaim NNA,et al. Association of Alzheimer's disease with genetic variants of apolipoprotein E, clusterin, TNF-α, and IL-6 among elderly saudis[J]. Curr Pharm Biotechnol, 2022,23(15):1893-1902. DOI: 10.2174/13892010236662202080- 93919.
[20] Cheng GW, Mok KK, Yeung SH, et al. Apolipoprotein E ε4 mediates myelin breakdown by targeting oligodendrocytes in sporadic Alzheimer disease[J]. J Neuropathol Exp Neurol, 2022,81(9):717-730.DOI: 10.1093/jnen/nlac054.
[21] Zhu D, Montagne A, Zhao Z. Alzheimer's pathogenic mechanisms and underlying sex difference[J]. Cell Mol Life Sci, 2021 ,78(11):4907-4920.DOI: 10.1007/s00018-021-03830-w.
[22] Watson Y, Nelson B, Kluesner JH,et al. Aggregate trends of apolipoprotein E on cognition in transgenic Alzheimer's disease mice[J]. J Alzheimers Dis, 2021,83(1):435-450.DOI: 10.3233/JAD-210492.
[23] Xing F, Meng T, Therriault J,et al. Apolipoprotein E ε4 and ε3 alleles associate with cerebrospinal fluid tau and cognition in the presence of amyloid-β in mild cognitive impairment but not in Alzheimer's disease[J]. J Integr Neurosci, 2021,20(2):277-286.DOI: 10.31083/j.jin2002027.
[24] 孙永存,谢莉红. AD患者脑电图δ+θ/α+β比值与炎症因子的相关性分析[J]. 西南国防医药,2016,26(10):1199-1201. DOI:10.3969/j.issn.1004-0188.2016.10.040.
[25] 郭敏,金迪,王培福,等. 阿尔茨海默病患者认知功能与其血清IL-6、hs-CRP、Hcy、CysC水平相关性分析[J]. 医学临床研究,2019,36(2):280-281,284. DOI:10.3969/ji.ssn.1671-7171.2019.02.022.
[26] 邓小莹,范永祥,莫志铭,等. 脑白质高信号患者血浆脂蛋白磷脂酶A2水平及其与认知功能障碍的关系[J]. 实用医学杂志,2021,37(7):884-888. DOI:10.3969/j.issn.1006- 5725. 2021.07.011.
|